

UCLA

UCLA Previously Published Works

Title

Effectiveness of the Ad26.COV2.S (Johnson & Johnson) COVID-19 Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States

Permalink

<https://escholarship.org/uc/item/5jz73379>

Journal

Clinical Infectious Diseases, 75(Suppl 2)

ISSN

1058-4838

Authors

Lewis, Nathaniel M
Self, Wesley H
Gaglani, Manjusha
et al.

Publication Date

2022-10-03

DOI

10.1093/cid/ciac439

Peer reviewed

1 **Effectiveness of the Ad26.COV2.S (Johnson & Johnson) COVID-19 Vaccine for Preventing COVID-19**
2 **Hospitalizations and Progression to High Disease Severity in the United States**

3

4 Nathaniel M. Lewis, PhD¹; Wesley H. Self, MD, MPH²; Manjusha Gaglani, MBBS^{5,6}; Adit A. Ginde, MD³;
5 David J. Douin, MD³; H. Keipp Talbot, MD²; Jonathan D. Casey, MD, MSc²; Nicholas M. Mohr, MD⁴; Anne
6 Zepeski, PharmD⁴; Shekhar A. Ghamande, MD⁵; Tresa A. McNeal, MD⁵; Nathan I. Shapiro, MD⁷; Kevin W.
7 Gibbs, MD⁸; D. Clark Files, MD⁸; David N. Hager, MD, PhD⁹; Arber Shehu, MD⁹; Matthew E. Prekker,
8 MD¹⁰; Heidi L. Erickson, MD¹⁰; Michelle N. Gong, MD¹¹; Amira Mohamed, MD¹¹; Nicholas J. Johnson,
9 MD¹²; Vasisht Srinivasan, MD¹²; Jay S. Steingrub, MD¹³; Ithan D. Peltan, MD¹⁴; Samuel M. Brown, MD¹⁴;
10 Emily T. Martin, PhD¹⁵; Arnold S. Monto, MD¹⁵; Akram Khan, MD¹⁵; Laurence W. Busse, MD¹⁶; Caitlin C.
11 ten Lohuis, ACNP-BC¹⁶; Abhijit Duggal, MD¹⁷; Jennifer G. Wilson, MD¹⁸; Alexandra June Gordon, MD¹⁸;
12 Nida Qadir, MD¹⁹; Steven Y. Chang, MD, PhD¹⁹; Christopher Mallow, MD²⁰; Carolina Rivas, BS²⁰; Hilary M.
13 Babcock, MD²¹; Jennie H. Kwon, DO, MSCI²¹; Matthew C. Exline, MD²²; Adam S. Luring, MD, PhD²³;
14 Natasha Halasa, MD, MPH²; James D. Chappell, MD, PhD²; Carlos G. Grijalva, MD²; Todd W. Rice, MD²;
15 Jillian P. Rhoads, PhD²; Ian D. Jones, MD²; William B. Stubblefield, MD²; Adrienne Baughman, BS²; Kelsey
16 N. Womack, PhD²; Christopher J. Lindsell, PhD²; Kimberly W. Hart, MA²; Yuwei Zhu, MD, MS²; Katherine
17 Adams, MPH¹; Manish M. Patel, MD¹; Mark W. Tenforde, MD, PhD¹; and IVY Network Collaborators

18

19 ¹CDC COVID-19 Response Team, Atlanta, GA, USA; ²Vanderbilt University Medical Center, Nashville,
20 Tennessee, USA; ³University of Colorado School of Medicine, Aurora, Colorado, USA; ⁴University of Iowa,
21 Iowa City, Iowa, USA; ⁵Baylor Scott & White Health, Temple, Texas, USA; ⁶Texas A&M University College
22 of Medicine, Temple, Texas, USA; ⁷Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA;
23 ⁸Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, USA; ⁹Johns Hopkins

1 Hospital, Baltimore, Maryland, USA; ¹⁰Hennepin County Medical Center, Minneapolis, Minnesota, USA;
2 ¹¹Montefiore Healthcare Center, Albert Einstein College of Medicine, Bronx, New York, USA; ¹²University
3 of Washington School of Medicine, Seattle, Washington, USA; ¹³Baystate Medical Center, Springfield,
4 Massachusetts, USA; ¹⁴Intermountain Medical Center and University of Utah, Salt Lake City, Utah, USA;
5 ¹⁵University of Michigan School of Public Health, Ann Arbor, Michigan, USA; ¹⁶Emory University School of
6 Medicine, Atlanta, Georgia, USA; ¹⁷Cleveland Clinic, Cleveland, Ohio, USA; ¹⁸Stanford University School of
7 Medicine, Palo Alto, California, USA; ¹⁹David Geffen School of Medicine at UCLA, Ronald Reagan-UCLA
8 Medical Center, Los Angeles, California, USA; ²⁰University of Miami, Miami, Florida, USA; ²¹Washington
9 University, St. Louis, Missouri, USA; ²²Ohio State University Wexner Medical Center, Columbus, Ohio,
10 USA; ²³University of Michigan School of Medicine, Ann Arbor, Michigan, USA.

11

12 **Corresponding Author**

13 Nathaniel M. Lewis, Influenza Prevention and Control Team, Influenza Division, Centers for Disease
14 Control and Prevention, 1600 Clifton Rd NE, Mailstop 46 24/7, Atlanta, Georgia, 30329 (pha6@cdc.gov).

15 **Running Title**

16 Effectiveness of the Ad26.COV2.S COVID-19 Vaccine

17

18

1 **Abstract**

2 **Background**

3 Adults in the United States (US) began receiving the viral vector COVID-19 vaccine, Ad26.COV2.S
4 (Johnson & Johnson [Janssen]), in February 2021. We evaluated Ad26.COV2.S vaccine effectiveness (VE)
5 against COVID-19 hospitalization and high disease severity during the first 10 months of its use.

6 **Methods**

7 In a multicenter case-control analysis of US adults (≥ 18 years) hospitalized March 11–December 15,
8 2021, we estimated VE against susceptibility to COVID-19 hospitalization (VEs), comparing odds of prior
9 vaccination with a single dose Ad26.COV2.S vaccine between hospitalized cases with COVID-19 and
10 controls without COVID-19. Among hospitalized patients with COVID-19, we estimated VE against
11 disease progression (VEp) to death or invasive mechanical ventilation (IMV), comparing odds of prior
12 vaccination between patients with and without progression.

13 **Results**

14 After excluding patients receiving mRNA vaccines, among 3,979 COVID-19 case-patients (5% vaccinated
15 with Ad26.COV2.S) and 2,229 controls (13% vaccinated with Ad26.COV2.S), VEs of Ad26.COV2.S against
16 COVID-19 hospitalization was 70% (95% CI: 63%–75%) overall, including 55% (29%–72%) among
17 immunocompromised patients, and 72% (64%–77%) among immunocompetent patients, for whom VEs
18 was similar at 14–90 days (73% [59%–82%]), 91–180 days (71% [60%–80%]), and 181–274 days (70%
19 [54%–81%]) post-vaccination. Among hospitalized COVID-19 case-patients, VEp was 46% (18%–65%)
20 among immunocompetent patients.

21 **Conclusions**

22 The Ad26.COV2.S COVID-19 vaccine reduced the risk of COVID-19 hospitalization by 72% among
23 immunocompetent adults without waning through 6 months post-vaccination. After hospitalization for
24 COVID-19, vaccinated immunocompetent patients were less likely to require IMV or die compared to
25 unvaccinated immunocompetent patients.

26 **Key words:** COVID-19, vaccine effectiveness, viral vector vaccines

27

1 Background

2 The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
3 resulted in more than 7 million hospitalizations and 890,000 deaths in the United States (US) through
4 January 2022¹. In February 2021, the SARS-CoV-2 viral vector vaccine (Ad26.COVS) from Johnson &
5 Johnson (Janssen), became the third of three vaccines (in addition to BNT162b2 from Pfizer-BioNTech
6 and mRNA-1273 from Moderna in December 2020) to be made available in the United States (US) for
7 adults aged ≥ 18 years under Emergency Use Authorization by the Food and Drug Administration (FDA).²
8 This vaccine employs a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector
9 encoding a full-length SARS-CoV-2 spike protein³ and has been shown in clinical trials^{4,5} and early
10 observational studies^{6,7} to be effective in preventing severe COVID-19.
11 Most people vaccinated against COVID-19 in the US have received one of the two mRNA COVID-19
12 vaccines (BNT162b2 or mRNA-1273). However, approximately 18 million doses of the Ad26.COVS
13 vaccine have been administered in the US through February 2022.¹ Less frequent use of the
14 Ad26.COVS vaccine may be due to later authorization than mRNA vaccines, limited availability in many
15 locations, lower estimated vaccine effectiveness (VE) compared with mRNA vaccines,⁶ or early reports of
16 adverse events including thrombosis with thrombocytopenia syndrome (TTS),^{8,9} leading to a temporary
17 suspension of use from April 13–23, 2021, followed by resumed use with a warning about the risk of
18 rare blood clotting events.⁹ In December 2021, the United States Centers for Disease Control and
19 Prevention (CDC) issued a preferential recommendation for the BNT162b2 and mRNA-1273 mRNA
20 vaccines over the Ad26.COVS vaccine for primary and booster vaccination.¹⁰
21 Due to its comparatively limited use, real-world evaluations of VE for the Ad26.COVS vaccine against
22 COVID-19 hospitalization⁶ have been relatively limited compared to those for mRNA vaccines.^{11–14}
23 However, in the US, the Ad26.COVS vaccine continues to have a role in preventing COVID-19, including
24 for persons with a contraindication to receipt of mRNA COVID-19 vaccines.⁹ In addition, Johnson and

1 Johnson plans to donate almost 100 million doses of Ad26.COVS2.S internationally through the COVAX
2 program led by the Coalition for Epidemic Preparedness Innovations, Gavi Vaccine Alliance, and the
3 World Health Organization.¹⁵ Therefore, evaluations to assess the real-world effectiveness of the
4 Ad26.COVS2.S vaccine against severe COVID-19 are important. Ongoing use of the Ad26.COVS2.S vaccine
5 in the US population since February 2021 means that evaluations of VE against hospitalization with
6 sufficient sample size to be meaningful are now possible. In this analysis, we evaluated two forms of
7 vaccine effectiveness¹⁶ of the Ad26.COVS2.S vaccine: (1) effectiveness in preventing susceptibility to
8 COVID-19-associated hospitalization (VEs), and (2) effectiveness against the progression of COVID-19 to
9 death or invasive mechanical ventilation (IMV) within 28 days of hospitalization (VEp) as a measure of
10 potential disease attenuation among vaccinated patients with COVID-19.

11 **Methods**

12 During March 11–December 15, 2021, adults admitted to 21 hospitals comprising the Influenza or Other
13 Viruses in the Acutely Ill Network (IVY Network) and who received testing for SARS-CoV-2 were enrolled.
14 The analysis comprised the timeframe during which SARS-CoV-2 Alpha (B.1.1.7) variant predominated
15 (March–June 2021) followed by the SARS-CoV-2 Delta (B.1.617.2 and AY sublineages) variant (July–
16 December 2021), and just before Omicron became the main circulating variant. VEs against COVID-19
17 hospitalization was evaluated for adults who received a single dose Ad26.COVS2.S vaccine ≥ 14 days
18 before illness onset. Methods have been described in detail elsewhere.^{6,12–15} In brief, case-patients had
19 COVID-19–like illness and received a positive SARS-CoV-2 test result (nucleic acid amplification test
20 [NAAT] or antigen test) within 10 days of illness onset. Control patients were either “test-negative”
21 controls hospitalized with signs or symptoms of an acute respiratory illness but testing negative for
22 SARS-CoV-2 by NAAT, or “syndrome-negative” controls hospitalized without signs or symptoms
23 of an acute respiratory illness and testing negative for SARS-CoV-2 by NAAT. Using standardized case
24 report forms, interviews with patients or proxies were used to collect demographic and clinical

1 characteristics and electronic medical record (EMR) searches were performed to collect information
2 about underlying medical conditions. Prior COVID-19 vaccination was verified primarily through source
3 documentation (including state vaccination registries, EMRs, and vaccination record cards) and
4 additionally through self-report including date and location of vaccination.

5 For patients hospitalized with COVID-19, we collected data on their clinical course until the outcome
6 that occurred earliest: death, hospital discharge, or 28 days after hospital admission if still admitted.
7 Disease severity was classified by dividing COVID-19 case patients into those who experienced death or
8 required IMV (i.e., a composite measure we refer to as progression to high disease severity) and those
9 who did not (i.e., no progression to high disease severity). Medical condition categories were defined
10 using standardized definitions and obtained through electronic medical record (EMR) review by trained
11 surveillance personnel. Persons with immunocompromising conditions were defined as those with one
12 or more of the following: active solid organ cancer; active hematologic cancer (such as leukemia,
13 lymphoma, or myeloma); HIV infection without AIDS; AIDS; congenital immunodeficiency syndrome;
14 previous splenectomy; prior solid organ, stem cell, or bone marrow transplant; use of
15 immunosuppressive medication; systemic lupus erythematosus; rheumatoid arthritis; psoriasis;
16 scleroderma; or inflammatory bowel disease, including Crohn's disease or ulcerative colitis
17 (Supplemental Table 1).

18 In this analysis of the effects of a single dose AD.26.COVID.2.S vaccine, participants who were vaccinated
19 with a single dose AD.26.COVID.2.S vaccine and those who were unvaccinated were analyzed. Enrolled
20 participants who received other vaccine products, such as an mRNA vaccine, or multiple doses of
21 AD.26.COVID.2.S were excluded from this analysis. VEs against COVID-19-associated hospitalization was
22 estimated using multivariable logistic regression, comparing the odds of being vaccinated with a single
23 dose Ad26.COVID.2.S vaccine among case-patients versus controls, adjusting for potential confounders
24 including admission date (biweekly intervals), geographic region (10 Health and Human Services

1 regions), age group (18–49, 50–64, or ≥65 years), sex, and self-reported race and Hispanic ethnicity. VEs
2 was calculated as $(1 - \text{adjusted odds ratio}) \times 100\%$. Results were stratified by age group, presence of 0 vs
3 ≥1 chronic medical conditions, presence of 0 vs ≥1 immunocompromising conditions, variant period
4 (Alpha vs Delta), and time since receipt of the vaccine (14–90 days, 91–180 days, and >180 days post-
5 vaccination). VE_p against progression to high disease severity was estimated by restricting analysis to
6 patients hospitalized with COVID-19. Here, we assessed the association between progression to death or
7 IMV and prior vaccination with Ad26.COV2.S using multivariable logistic regression. These models
8 adjusted for age group, sex, race and Hispanic ethnicity, and number of chronic medical conditions, and
9 results were stratified by age group and presence of 0 versus ≥1 immunocompromising conditions. VE_p
10 was calculated as $(1 - \text{adjusted odds ratio}) \times 100\%$. Analyses were conducted using R (Vienna, Austria)
11 and STATA (College Station, Texas). This activity was reviewed by CDC and was conducted consistent
12 with applicable federal law and CDC policy, e.g., 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C.
13 §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq.

14 **Results**

15 A total of 12,524 adults were enrolled in the IVY study from March 11 through December 15, 2021. Of
16 these, 6,316 were excluded because they met one or more exclusion criteria for the current analysis,
17 most commonly because they received a mRNA vaccine product [n=6038] as a primary or booster dose.
18 A total of 6,208 adults, including 3979 cases with laboratory-confirmed COVID-19 (5% vaccinated with
19 Ad26.COV2.S) and 2229 controls without COVID-19 (13% vaccinated with Ad26.COV2.S, $p < 0.002$) met
20 inclusion criteria for this analysis. Compared with control patients, case patients were younger (median
21 age [IQR]: 53 [40–64] vs 56 [42–66], $p = 0.002$), more likely to be employed (48% vs 26%, $p < 0.001$) and to
22 be employed as a healthcare worker specifically (5% vs 3%, $p = 0.003$) and less likely to be a long-term
23 care facility resident (2% vs 4%, $p < 0.001$), to have been hospitalized for any cause during the past year
24 (24% vs 57%, $p < 0.001$) to have ≥1 chronic medical condition (68% vs 85%, $p < 0.001$), to currently use

1 tobacco (11% vs 28%, $p < 0.001$), or to report a prior laboratory-confirmed SARS-CoV-2 infection (3% vs
2 12%, $p < 0.001$). Median (IQR) number of days from vaccine dose 1 to illness onset was greater for case
3 patients (140 [85–193]) compared with control patients (127 [69–183], $p = 0.0049$) (Table 1).

4 *VEs Against Hospitalization with COVID-19*

5 Overall adjusted VEs (95% CI) for a single dose Ad26.COV2.S vaccine against COVID-19 hospitalization
6 was 70% (63%–75%) and was lower in patients who were immunocompromised (55% [31%–72%]) than
7 those who were immunocompetent (72% [64%–77%]). Among immunocompetent patients, VEs was
8 higher (75% [67%–82%]) among patients aged 18–64 years than for those aged ≥ 65 years (66% [50%–
9 77%]). VEs was similar between periods in which the Alpha variant (68% [43%–83%]) and Delta variant
10 (72% [64%–78%]) predominated and remained similar 14–90 days (73% [60%–82%]), 91–180 days (71%
11 [59%–80%]), and > 180 days (70% [53%–81%]) post-vaccination. Finally, VEs was higher in patients
12 without chronic medical conditions (86% [74%–93%]) than those with ≥ 1 chronic medical condition (64%
13 [54%–73%]) (Figure 1, Supplementary Table 2).

14 *VEp Against Progression to High Disease Severity*

15 Of 3,979 COVID-19 case patients, 3,940 (95%) had complete data on clinical outcomes. Among these
16 patients, COVID-19 patients vaccinated with a single dose Ad26.COV2.S vaccine were less likely to
17 experience many severe clinical outcomes compared with unvaccinated COVID-19 patients, including
18 invasive mechanical ventilation (18% vs 24%, $p = 0.0304$), non-invasive ventilation (12% vs 17%, $p = 0.050$),
19 high-flow oxygen therapy (30% vs 40%, $p = 0.011$), and vasopressor use (16% vs 23%, $p = 0.025$).
20 Vaccinated COVID-19 patients were less likely to experience high disease severity, defined as the
21 composite of death or IMV, than unvaccinated COVID-19 patients (20% vs 27%, $p = 0.030$) (Table 2). VEp
22 (95% CI) was 36% (7%–56%) overall, and similar for immunocompetent patients (46% [18%–65%]),

1 patients aged 18–64 years (31% [11%–58%]) and patients aged ≥65 years (47% [4%–71%]). No VE_p was
2 observed among immunocompromised patients (-29% [-186%–42%]) (Figure 2, Supplementary Table 3).

3 **Discussion**

4 Vaccination with a single dose Ad26.COVS vaccine reduced the risk of COVID-19 hospitalization by
5 more than two thirds; this was higher in immunocompetent persons compared with those who were
6 immunocompromised. Protection against hospitalization was also sustained and stable through 6 or
7 more months post-vaccination. Moreover, among patients hospitalized with COVID-19, prior vaccination
8 with Ad26.COVS, compared with being unvaccinated, was associated with a lower risk of severe
9 outcomes including a reduced composite risk of IMV or death.

10 The overall VEs against hospitalized COVID-19 observed in this analysis (70%) was similar to the vaccine
11 efficacy against severe–critical COVID-19 (75%) demonstrated in a phase III randomized-controlled trial
12 (RCT) of the 1-dose Ad26.COVS vaccine.⁵ As severe outcomes are rare in clinical trials and adults with
13 more severe underlying medical conditions are frequently under-represented in RCTs, results from this
14 study and other post-marketing observational studies are critical to understanding the real-world
15 effectiveness of COVID-19 vaccines. Importantly, among immunocompetent COVID-19 case-patients
16 vaccination was associated with a lower risk (by 46%) of progressing to severe outcomes including death
17 or IMV compared to unvaccinated patients. These results are largely consistent with a cohort study of
18 US veterans that also found a substantial reduction in severe outcomes including death among
19 Ad26.COVS vaccine recipients.⁷ Although the VE estimates for Ad26.COVS are lower than those
20 observed for mRNA COVID-19 vaccines,^{6,11–14} the vaccine still provides substantial protection against
21 severe COVID-19 with little waning for at least six months. Vaccines using Ad26-based vectors can be
22 stored long-term either frozen or at 2–8 °C, enabling product distribution through existing vaccine
23 supply chains. These vaccines have also been shown to be stable inside of syringes and needles, and
24 when subjected to agitation or temperature excursions.¹⁷ Importantly, real-world effectiveness of the

1 Ad26.COVS vaccine could still vary across regions based on pre-existing immunity to Ad26 and its
2 effects on vaccine immunogenicity,¹⁷ and further evaluation will be necessary.

3 The Ad26.COVS vaccine showed stable VE over time including among those patients >180 days from
4 vaccination (100% of which became ill during the period of Delta variant predominance), suggesting
5 stability of VE over the period pre-dating Omicron variant circulation and reinforcing that the protection
6 for ≥ 6 months observed in clinical trials⁵ generalizes to a real world setting with a high prevalence of
7 medically complex patients. In addition, VEs for the Ad26.COVS vaccine was similar during the Delta-
8 predominant period and Alpha-predominant periods, suggesting that protection was observed across
9 two different SARS-CoV-2 variants,^{18,19} although it may have been reduced against Omicron given the
10 reduced effectiveness observed for mRNA vaccines.²⁰ Although a second dose of Ad26.COVS, or
11 alternatively, an mRNA vaccine, ≥ 2 months from the first dose is now recommended for recipients of the
12 Ad26.COVS vaccine,^{17,21} our results showed that a single dose Ad26.COVS vaccine remained
13 reasonably effective against the Delta variant over time from vaccination and across periods of different
14 variant predominance. This minimal waning observed here reinforces preexisting evidence of durable
15 humoral and cellular immune responses to ad26 vaccines, which use a non-replicating viral vector that
16 enters the nucleus of cells to induce an immune response.²²

17 We also found that Ad26.COVS vaccination attenuated the likelihood of progression to severe disease
18 among those who were hospitalized with COVID-19 despite vaccination. While VEP against progression
19 to high disease severity was substantial for immunocompetent persons (46%), the Ad26.COVS vaccine
20 appeared ineffective in preventing progression to high severity in immunocompromised patients. Data
21 are lacking on differences in disease attenuation between immunocompromised and
22 immunocompetent populations. However, a growing body of literature suggests that
23 immunocompromised patients, including transplant recipients and patients with cancer, have
24 diminished humoral and cellular immune responses to mRNA and inactivated SARS-CoV-2 vaccines.²³⁻²⁵

1 Our results suggest that the immune response to a single dose Ad26.COVS vaccine among
2 immunocompromised patients may be insufficient to attenuate disease severity in patients who have
3 been hospitalized with COVID-19.

4 Our findings must be considered in the context of several limitations. First, this analysis focused
5 exclusively on protection from a single dose of the Ad26.COVS vaccine and did not evaluate multiple
6 doses of the vaccine or the Ad26.COVS vaccine combined with mRNA vaccine doses. Additional doses
7 of vaccine would likely increase vaccine effectiveness.^{17,21} Second, while we found overall lower VE for
8 patients with immunocompromising conditions, this analysis was not powered to look at VE for specific
9 immunocompromising conditions. Third and relatedly, it is possible that the types of
10 immunocompromising conditions reported among patients included in this analysis who received the
11 Ad26.COVS vaccine were different than those who received mRNA vaccines (i.e., due to different
12 vaccine indications for different conditions) and could have affected VEs and VE_p for this subgroup.
13 Fourth, while we did not assess for waning of VE over time since vaccination within periods of different
14 variant predominance, no meaningful decline in VE was observed for either metric. Fifth, VE associated
15 with newly emergent variants was not assessed. Sixth, VE was not assessed against SARS-CoV-2 infection
16 or mild illness. Finally, although VE estimates were adjusted for relevant potential confounders, residual
17 confounding is possible.

18 **Conclusions**

19 A single dose Ad26.COVS vaccine provided substantial protection against severe COVID-19 throughout
20 2021 in this real-world observational study, consistent with vaccine efficacy reported in clinical trials of
21 Ad26.COVS conducted in 2020. Although the observed vaccine effectiveness for Ad26.COVS was
22 lower than that described for mRNA COVID-19 vaccines, a single dose of Ad26.COVS did result in
23 strong protection against severe COVID-19 for at least 6 months in immunocompetent populations. The

1 Ad26.COV2.S vaccine is an important alternative to mRNA COVID-19 vaccines for those who are unable
2 to receive an mRNA vaccine.

3 NOTES

4 **Disclaimer**

5 The findings and conclusions in this report are those of the authors and do not necessarily represent the
6 official position of the Centers for Disease Control and Prevention.

7 **Funding**

8 Centers for Disease Control and Prevention funded this work through payments to each participating
9 institution.

10 **Potential conflicts**

11 **M Gaglani:** CDC: BSWH US Flu/COVID VE Newtork, HAIVEN, Synergy studies; CDC-Abt: BSWH FluVax Trial
12 and RECOVER-PROTECT Cohort Studies; CDC-Westat: BSWH VISION COVID-Flu VE Study; Janssen: BSWH
13 RSV Severity App Birth Cohort Study; Co-Chair of Infectious Diseases and Immunization Committee –
14 Texas Pediatric Society – Texas Chapter of American Academy of Pediatrics; **A Ginde:** NIH, Department
15 of Defense; Faron Pharmaceuticals; AbbVie; D Douin: NIH/NIGMS Institutional Training Grant; **J Casey:**
16 NIH and Department of Defense grants unrelated to this work; **T McNeal:** Panelist for Society of Hospital
17 Medicine Updates in Heart Failure; Board member for Scott & White Clinic Physicians Board of Directors;
18 **K Gibbs:** NECTAR Executive Committee member ACTIV4-HT; **DC Files:** Cytovale consulting fees; Medpace
19 Data Safety Monitoring Board; **DN Hager:** NHLBI participant in the ACTIV4d-Host Tissue Trial; Chair
20 DSMD – SAFE EVICT Trial of VIT C in COVID-19; **MIN Gong:** Grants from NHLBI and AHRQ; Consulting fees
21 for Endpoint for scientific advisory panel; Honoraria – Medicine Grand Rounds from Westchester
22 Medical Center; Support for attending ATS Board of Directors meeting; DSMB for Regeneron study and
23 REPLENISH trial; **NJ Johnson:** NIH grants paid to University of Washington Royalty Research Fund;

1 Department of Defense grants; Medic One Foundation grants; WA Department of Health expert
2 testimony payment; DSMB for Opticyte, Inc.; Chair, ACEP Critical Care Section; **I Peltan**: NIH grants;
3 Regeneron Pharmaceuticals grant; Intermountain Research & Medical Foundation grant; Asahi Kasei
4 Pharma grant; Janssen Pharmaceuticals grant; **S Brown**: NIH grants and Department of Defense grants;
5 DSMB for Hamilton ventilators and NYU; **ET Martin**: Merck grant; **AS Monto**: NIH grant; **A Khan**: NIH
6 grants; United Therapeutics grants; Eli Lilly grants; Johnson&Johnson – BOA Medical – 4DMedical
7 research grants; A Duggal: Center PI for PETAL network through NHLBI grant; On steering committee for
8 A Lung technologies; **JG Wilson**: NIH/NHLBI funding for ACTIV-3 and ACTIV-4 trials; American Board of
9 Internal Medicine – member of Critical Care Exam Committee; **SY Chang**: Consulting fees for PureTech
10 Health and Kiniska Pharmaceuticals; Honoraria for La Jolla; **HM Babcock**: CDC grant for HCP COVID
11 vaccine effectiveness; JH Kwon: NIAID grant; **MC Exline**: Abbott Labs honoraria for speaking on ASPEN
12 on nutrition in critical illness from COVID; **A Lauring**: grants from CDC, NIH and Burroughs Wellcome
13 Fund; consulting fees from Sanofi on antiviral drugs and for Roche on baloxavir trial steering committee;
14 **N Halasa**: grants from NIH, Quidel and Sanofi; Honoraria for speaking at CME event at AAP; **CG Grijalva**:
15 grants from Campbell Alliance/Syneos Health, Sanofi, CDC, AHRQ, NIH and FDA; consulting fees from
16 Merck, Pfizer, and Sanofi-Pasteur; **TW Rice**: grants from NIH, Department of Defense and AbbVie;
17 consulting fees for Cumberland Pharmaceuticals, Inc. and Cytovale, Inc.; DSMB for Sanofi, Inc.;
18 Immediate Past President – ASPEN; Stock in Cumberland Pharmaceuticals, Inc. for consulting work; **WB**
19 **Stubblefield**: NIH training grants; **CJ Lindsell**: grants from NIH, Department of Defense; CDC;
20 bioMerieux; Entegriion, Inc.; Endpoint Health; AbbVie; Patents for risk stratification in sepsis and septic
21 shock issued to Cincinnati Children’s Hospital Medical Center; DSMBs for clinical trials for Study Principal
22 Investigators; Association for Clinical and Translational Science (Executive Committee, Immediate Past
23 President, and Board of Directors); Stock options in Bioscape Digita; The remaining authors have no
24 potential conflicts

1 **References**

- 2 1. Centers for Disease Control and Prevention. COVID data tracker. Accessed September 28,
3 2021. Available at: <https://covid.cdc.gov/covid-data-tracker/#datatracker-home>.
- 4 2. Oliver SE, Gargano JW, Scobie H, et al. The Advisory Committee on Immunization Practices'
5 Interim Recommendation for Use of Janssen COVID-19 Vaccine – United States, February
6 2021. *MMWR Morb Mortal Wkly Rep* 2021;70(9):329–332.
- 7 3. Livingston EH, Malani PN, Creech CB. The Johnson & Johnson Vaccine for COVID-19. *JAMA*
8 2021;325(15):1575.
- 9 4. Sadoff J, Le Gars M, Shukarev G, et al. Interim Results of a Phase 1–2a Trial of Ad26.COV2.S
10 Covid-19 Vaccine. *N Engl J Med* 2021; 384:1824–1835.
- 11 5. Sadoff J, Gray G, Vandebosch A, et al. Final Analysis of Efficacy and Safety of Single-Dose
12 Ad26.COV2.S. *N Engl J Med* 2021 (February 9), DOI: 10.1056/NEJMoa2117608.
- 13 6. Self WH, Tenforde MW, Rhoads JP, et al. Comparative Effectiveness of Moderna, Pfizer-
14 BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19
15 Hospitalizations Among Adults Without Immunocompromising Conditions - United States,
16 March–August 2021. *MMWR Morb Mortal Wkly Rep* 2021;70(38):1337–1343.
- 17 7. Cohn BA, Cirillo PM, Murphy CC, Krigbaum NY, Wallace AW. SARS-CoV-2 vaccine protection
18 and deaths among US veterans during 2021. *Science* 375(6578):331–336.
- 19 8. Shay DK, Gee J, Su JR, et al. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19
20 Vaccine — United States, March–April 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:680–
21 684.

22

23

- 1 9. MacNeil JR, Su JR, Broder KR, et al. Updated Recommendations from the Advisory
2 Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19
3 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine
4 Recipients — United States, April 2021. *MMWR Morb Mortal Wkly Rep* 2021;70(17):651–
5 656.
- 6 10. Oliver SE, Wallace M, See I, et al. Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine:
7 Updated Interim Recommendations from the Advisory Committee on Immunization
8 Practices — United States, December 2021. *MMWR Morb Mortal Wkly Rep* 2022;71:90–95.
- 9 11. Tenforde MW, Patel MM, Ginde AA, et al. Effectiveness of SARS-CoV-2 mRNA Vaccines for
10 Preventing Covid-19 Hospitalizations in the United States. *Clin Infect Dis* 2021 Aug 6:ciab687.
- 11 12. Tenforde MW, Self WH, Naioti EA, et al. Sustained Effectiveness of Pfizer-BioNTech and
12 Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults – United
13 States, March-July 2021. *MMWR Morb Mortal Wkly Rep* 2021;70(34):1156–1162.
- 14 13. Lewis NM, Naioti EA, Self WH, et al. Effectiveness of mRNA Vaccines Against COVID-19
15 Hospitalization by Age and Chronic Medical Conditions Burden Among Immunocompetent
16 US Adults, March-August 2021. *J Infect Dis* 2021:jiab619.
- 17 14. Tenforde MW, Self WH, Adams K, et al. Association Between mRNA Vaccination and COVID-
18 19 Hospitalization and Disease Severity. *JAMA* 2021;326(20):2043–2054.
- 19 15. Johnson & Johnson. Almost 100 million Doses of Johnson & Johnson COVID-19 Vaccine to be
20 Donated to Lower Income Countries Through COVAX. Accessed February 2, 2022. Available
21 at: [https://www.jnj.com/almost-100-million-doses-of-johnson-johnson-covid-19-vaccine-to-](https://www.jnj.com/almost-100-million-doses-of-johnson-johnson-covid-19-vaccine-to-be-donated-to-low-income-countries-through-covax)
22 [be-donated-to-low-income-countries-through-covax.](https://www.jnj.com/almost-100-million-doses-of-johnson-johnson-covid-19-vaccine-to-be-donated-to-low-income-countries-through-covax)

- 1 16. Halloran ME, Longini IM, Struchiner CJ. Overview of Vaccine Effects and Study Designs. In:
2 Halloran ME, Longini IM, Struchiner CJ. *Design and Analysis of Vaccine Studies. Statistics for*
3 *Biology and Health*. Springer; 2010:19–45.
- 4 17. Moore JP. Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral
5 Variants and Vaccine Efficacy. *JAMA* 2021;325(13):1251–1252.
- 6 18. Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly effective mRNA vaccines for
7 COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv [Preprint]. 2021
8 Aug 21:2021.08.06.21261707.
- 9 19. Bernal JL, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the
10 B.1.617.2 (Delta) Variant. *N Engl J Med* 2021; 385:585–594.
- 11 20. Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association Between 3 Doses of mRNA COVID-
12 19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta
13 Variants. *JAMA* 2022;327(7):639–651.
- 14 21. Mbaeyi S, Oliver SE, Collins JP, et al. The Advisory Committee on Immunization Practices’
15 Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines
16 — United States, 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:1545–1552.
- 17 22. Custers J, Kim D, Leyssen M, et al. Vaccines based on replication incompetent Ad26 viral
18 vectors: Standardized template with key considerations for a risk/benefit assessment.
19 *Vaccine* 2021;39(22):3081–3101.
- 20 23. Bruminhent, J, Setthaudom, C, Chaumdee, P, et al. SARS-CoV-2-specific humoral and cell-
21 mediated immune responses after immunization with inactivated COVID-19 vaccine in
22 kidney transplant recipients (CVIM 1 study). *Am J Transplant* 2021; 00:1–10.

- 1 24. Stock PG, Henrich TJ, Segev DL, Werbel WA. Interpreting and addressing suboptimal
2 immune responses after COVID-19 vaccination in solid-organ transplant recipients. *J Clin*
3 *Invest* 2021;131(14):e151178.
- 4 25. Lustig Y, Sapir E, Regev-Yochay G, et al. BNT162b2 COVID-19 vaccine and correlates of
5 humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort
6 study in health-care workers. *Lancet Resp Med* 2021; 9(9): 999–1009.
- 7

ACCEPTED MANUSCRIPT

1 **Table 1. Characteristics of Patients Vaccinated with One Dose of Ad26.COVID-19 (Johnson & Johnson),**
 2 **COVID-19 Case Patients and Control Patients, IVY Network**

| Characteristic, n/N (%) | Total (n=6208) | Case Patients (n=3979) | Control Patients (n=2229) | P-value |
|--|------------------|------------------------|---------------------------|---------|
| Clinical Group | | | | |
| Vaccinated with One Dose of Ad26.COVID-19 | 478/6208 (7.7) | 192/3979 (4.8) | 286/2229 (12.8) | <0.001 |
| Age in years | | | | |
| Median (IQR) | 54 (41–65) | 53 (40–64) | 56 (42–66) | 0.002 |
| 18–49 years | 2481/6208 (40.0) | 1638/3979 (41.2) | 843/2229 (37.8) | 0.006 |
| 50–64 years | 2103/6208 (33.9) | 1348/3979 (33.9) | 755/2229 (33.9) | |
| ≥65 years | 1624/6208 (26.2) | 993/3979 (25.0) | 631/2229 (28.3) | |
| Female sex | 2939/6208 (47.3) | 1873/3979 (47.1) | 1066/2229 (47.8) | 0.569 |
| Race/ethnicity^b | | | | |
| Non-Hispanic White | 3208/6208 (51.7) | 1985/3979 (49.9) | 1223/2229 (54.9) | <0.001 |
| Non-Hispanic Black | 1515/6208 (24.4) | 937/3979 (23.5) | 578/2229 (25.9) | |
| Hispanic, any race | 1083/6208 (17.4) | 787/3979 (19.8) | 296/2229 (13.3) | |
| Non-Hispanic, all other races | 286/6208 (4.6) | 192/3979 (4.8) | 94/2229 (4.2) | |
| Unknown | 116/6208 (1.9) | 78/3979 (2.0) | 38/2229 (1.7) | |
| US Census Region^c | | | | |
| Northeast | 894/6208 (14.4) | 592/3979 (14.9) | 302/2229 (13.5) | 0.407 |
| South | 2565/6208 (41.3) | 1624/3979 (40.8) | 941/2229 (42.2) | |
| Midwest | 1451/6208 (23.4) | 922/3979 (23.2) | 529/2229 (23.7) | |
| West | 1298/6208 (20.9) | 841/3979 (21.1) | 457/2229 (20.5) | |
| LTCF Resident | 159/5963 (2.7) | 76/3821 (2.0) | 83/2142 (3.9) | <0.001 |
| Employed | 1987/4959 (40.1) | 1513/3126 (48.4) | 474/1833 (25.9) | <0.001 |
| Healthcare worker | 222/4959 (4.5) | 161/3126 (5.2) | 61/1833 (3.3) | 0.003 |
| ≥1 previous hospitalization in the last year | 2075/5714 (36.3) | 882/3633 (24.3) | 1193/2081 (57.3) | <0.001 |
| ≥1 chronic medical condition^d | 4619/6207 (74.4) | 2716/3978 (68.3) | 1903/2229 (85.4) | <0.001 |
| Current tobacco use | 935/5345 (17.5) | 382/3382 (11.3) | 553/1963 (28.2) | <0.001 |
| Self-reported previous laboratory-confirmed SARS- | 381/6207(6.1) | 108/3978 (2.7) | 273/2229 (12.2) | <0.001 |

| CoV-2 infection | | | | |
|---|--------------|----------------|----------------|-------|
| Days from vaccine dose 1 to illness onset, median (IQR) | 135 (75-185) | 140 (84.5-193) | 126.5 (69-183) | 0.049 |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

Data are No./total No. (%) except where indicated.

Abbreviations: COVID-19, coronavirus disease 2019; IQR, interquartile range; LTFC, long-term care facility; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

^aHospitals by region were Northeast: Baystate Medical Center (Springfield, MA), Beth Israel Deaconess Medical Center (Boston, MA), Montefiore Medical Center (Bronx, NY); South: Vanderbilt University Medical Center (Nashville, TN), University of Miami Medical Center (Miami, FL), Emory University Medical Center (Atlanta, GA), Johns Hopkins Hospital (Baltimore, MD), Wake Forest University Baptist Medical Center (Winston-Salem, NC), Baylor Scott and White Health (Temple, TX); Midwest: University of Iowa Hospitals and Clinics (Iowa City, IA), University of Michigan Hospital (Ann Arbor, MI), Hennepin County Medical Center (Minneapolis, MN), Barnes-Jewish Hospital (St Louis, MO), Cleveland Clinic (Cleveland, OH), Ohio State University Wexner Medical Center (Columbus, OH); West: Stanford University Medical Center (Stanford, CA), UCLA Medical Center (Los Angeles, CA), UCHealth University of Colorado Hospital (Aurora, CO), Oregon Health and Science University Hospital (Portland, OR), Intermountain Medical Center (Murray, UT), University of Washington (Seattle, WA).

^bRacial and ethnic groups were reported by the patient or proxy.

^cNortheast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia; West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.

^dChronic medical conditions were obtained through medical chart review by trained personnel and classified by condition category specified in the table; a full list of conditions is included in Supplementary Table 1.



1 **FIGURE LEGENDS**

2 **Figure 1. Vaccine Effectiveness Against Susceptibility to COVID-19 Hospitalization (VEs) for Single Dose**
3 **Ad26.COVS.S (Johnson & Johnson) COVID-19 Vaccine Overall and by Subgroups, IVY Network^a**

4 ^aVaccine effectiveness models for immunocompetency, variant period, time since vaccination, and
5 conditions were adjusted for admission date (in biweekly intervals), US Health and Human Services
6 Region, self-reported race and Hispanic ethnicity, age (18-49, 50-64, and ≥ 65 years of age), and sex. The
7 model for age group adjusted for age in years as a continuous variable.

8


9 **Figure 2. Vaccine Effectiveness Against Progression to Invasive Mechanical Ventilation or to Death**
10 **within 28 days (VEp) for Single Dose Ad26.COVS.S (Johnson & Johnson) COVID-19 Vaccine Among**
11 **Adults Hospitalized With COVID-19, IVY Network^a**

12 ^aVaccine effectiveness models adjusted for age, sex, race and Hispanic ethnicity, and number of
13 underlying medical conditions (as 0, 1, 2, 3, or ≥ 4 categories of conditions). The model for age group
14 adjusted for age in years as a continuous variable.

15

16

ACCEPTED MANUSCRIPT



1
2
3
4

Figure 1
165x136 mm (.60 x DPI)



2
3
4

Figure 2
165x186 mm (.60 x DPI)